XueBiJing Injection Versus Placebo for Critically Ill Patients with Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.
Yuanlin Song,Chen Yao,Yongming Yao,Hui Han,Xiaodong Zhao,Kaijiang Yu,Luyi Liu,Ying Xu,Zhongmin Liu,Qingshan Zhou,Ying Wang,Zhuang Ma,Youguang Zheng,Dawei Wu,Zhongzhi Tang,Minzhou Zhang,Shuming Pan,Yanfen Chai,Yan Song,Jian Zhang,Lei Pan,Yi Liu,He Yu,Xuezhong Yu,Hong Zhang,Xiaoge Wang,Zhaohui Du,Xianyao Wan,Yijun Tang,Yingping Tian,Yimin Zhu,Hongliang Wang,Xiaoyan Yan,Zhi Liu,Boli Zhang,Nanshan Zhong,Hongcai Shang,Chunxue Bai
DOI: https://doi.org/10.1097/ccm.0000000000003842
IF: 8.8
2019-01-01
Critical Care Medicine
Abstract:Objectives: To investigate whether XueBiJing injection improves clinical outcomes in critically ill patients with severe community-acquired pneumonia. Design: Prospective, randomized, controlled study. Setting: Thirty-three hospitals in China. Patients: A total of 710 adults 18-75 years old with severe community-acquired pneumonia. Interventions: Participants in the XueBiJing group received XueBiJing, 100mL, q12 hours, and the control group received a visually indistinguishable placebo. Measurements and Main Results: The primary outcome was 8-day improvement in the pneumonia severity index risk rating. Secondary outcomes were 28-day mortality rate, duration of mechanical ventilation and total duration of ICU stay. Improvement in the pneumonia severity index risk rating, from a previously defined endpoint, occurred in 203 (60.78%) participants receiving XueBiJing and in 158 (46.33%) participants receiving placebo (between-group difference [95% CI], 14.4% [6.9-21.8%]; p < 0.001). Fifty-three (15.87%) XueBiJing recipients and 84 (24.63%) placebo recipients (8.8% [2.4-15.2%]; p = 0.006) died within 28 days. XueBiJing administration also decreased the mechanical ventilation time and the total ICU stay duration. The median mechanical ventilation time was 11.0 versus 16.5 days for the XueBiJing and placebo groups, respectively (p = 0.012). The total duration of ICU stay was 12 days for XueBiJing recipients versus 16 days for placebo recipients (p = 0.004). A total of 256 patients experienced adverse events (119 [35.63%] vs 137 [40.18%] in the XueBiJing and placebo groups, respectively [p = 0.235]). Conclusions: In critically ill patients with severe community-acquired pneumonia, XueBiJing injection led to a statistically significant improvement in the primary endpoint of the pneumonia severity index as well a significant improvement in the secondary clinical outcomes of mortality, duration of mechanical ventilation and duration of ICU stay.